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Abstract
Interaction between the hepatitis C virus (HCV) envelope protein E2 and the host receptor CD81 is essential for HCV entry
into target cells. The number of E2-CD81 complexes necessary for HCV entry has remained difficult to estimate
experimentally. Using the recently developed cell culture systems that allow persistent HCV infection in vitro, the
dependence of HCV entry and kinetics on CD81 expression has been measured. We reasoned that analysis of the latter
experiments using a mathematical model of viral kinetics may yield estimates of the number of E2-CD81 complexes
necessary for HCV entry. Here, we constructed a mathematical model of HCV viral kinetics in vitro, in which we accounted
explicitly for the dependence of HCV entry on CD81 expression. Model predictions of viral kinetics are in quantitative
agreement with experimental observations. Specifically, our model predicts triphasic viral kinetics in vitro, where the first
phase is characterized by cell proliferation, the second by the infection of susceptible cells and the third by the growth of
cells refractory to infection. By fitting model predictions to the above data, we were able to estimate the threshold number
of E2-CD81 complexes necessary for HCV entry into human hepatoma-derived cells. We found that depending on the E2-
CD81 binding affinity, between 1 and 13 E2-CD81 complexes are necessary for HCV entry. With this estimate, our model
captured data from independent experiments that employed different HCV clones and cells with distinct CD81 expression
levels, indicating that the estimate is robust. Our study thus quantifies the molecular requirements of HCV entry and
suggests guidelines for intervention strategies that target the E2-CD81 interaction. Further, our model presents a framework
for quantitative analyses of cell culture studies now extensively employed to investigate HCV infection.
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Introduction
HCV entry into target cells is a complex process involving the
interactions of the viral envelope proteins E1 and E2 and several
cell surface receptors, namely, scavenger receptor class B type I
(SR-BI) [1], the tetraspanin CD81 [2,3], and the tight junction
proteins claudin-1 (CLDN1) [4] and occludin [5]. Several recent
studies suggest a central role for CD81 in HCV entry: E2 has been
shown to interact directly with SR-BI and CD81 following viral
attachment to a target cell [1,2]. Patient derived neutralizing
antibodies appear to target the CD81 binding domains on E2 [6].
Indeed, anti-CD81 antibodies were able to block infection in vitro
[3] and in a mouse model [7]. Graft reinfection following liver
transplantation was observed recently to select for HCV strains
capable of more efficient entry, achieved partly through mutations
in the CD81 binding domains on E2 [8]. Expression of human
CD81 and occludin was essential for infection of genetically
humanized mice [7]. Besides, CLDN1 appears to mediate HCV
entry through its association with CD81 [9,10]. Consequently, the
E2-CD81 interaction presents a potent target for intervention;
drugs that block the E2-CD81 interaction are currently under
development [11,12].
How many E2-CD81 complexes must be formed between a
virion and a target cell to enable HCV entry? Knowledge of this
threshold would determine the number of E2-CD81 complexes
that a drug or a vaccine must prevent from forming in order to
block viral entry, thus presenting a quantitative guideline for
intervention strategies targeting the E2-CD81 interaction. This
threshold is currently unknown. Direct observation of the number
of E2-CD81 complexes formed before HCV entry has not been
possible. Recent cell culture studies have determined the
dependence of viral entry and kinetics in vitro on the CD81
expression level on target cells [10,13–18]. In particular, cells
expressing higher levels of CD81 were found to be more
susceptible to infection [13]. Further, the frequency of cells with
low CD81 expression typically increased with time following the
exposure of cells to HCV [14,15]. We reasoned that analysis of
these observations using a mathematical model of viral kinetics,
akin to studies of HIV entry (for example, see [19,20]), may allow
estimation of the threshold number of E2-CD81 complexes
necessary for HCV entry. While models of HCV viral kinetics in
vivo have been employed successfully to analyse patient data and
elucidate guidelines for treatment [21–31], models of HCV viral
kinetics in vitro have just begun to be formulated.
PLoS Computational Biology | www.ploscompbiol.org 1 December 2011 | Volume 7 | Issue 12 | e1002307Here, we constructed a mathematical model of HCV viral
kinetics in vitro that mimics cell culture studies of the dependence
of viral entry and kinetics on CD81 expression. Model predictions
captured data from several independent experiments quantitative-
ly and yielded estimates of the threshold number of E2-CD81
complexes necessary for HCV entry.
Results
Model formulation
We considered in vitro experiments where a population of
target cells, T, with a known distribution of the CD81 expression
level across cells is exposed to a population of HCVcc (cell culture
adapted) virions, V, and the progression of infection followed [13–
15]. We modelled the ensuing viral kinetics as follows (Fig. 1). We
first considered a single virus-cell pair with the virus attached to
the cell by interactions that precede E2-CD81 binding [12]. E2
and CD81 then interact to form E2-CD81 complexes. We
computed the mean number of these complexes formed at
equilibrium, NC, as a function of the CD81 expression level, ni,
on the cell. Assuming that the number of complexes formed, NC,
followed a Poisson distribution with mean NC, we computed the
probability, Si, that NC was larger than a threshold number NT
C.
We assumed that viral entry (and subsequently infection) occurred
if NC§NT
C (Fig. 1A). Thus, Si yielded the relative susceptibility to
infection of a cell with CD81 expression level ni.
We next considered the population of cells exposed to virions
(Fig. 1B). We divided the cells into different subpopulations Ti
with distinct CD81 expression levels ni and hence different
susceptibilities Si,w h e r ei~1, 2,:::,K. Cells in each subpopula-
tion were assumed to proliferate, die, or be infected at a rate
proportional to Si. The resulting infected cells, Ii, were lost at
enhanced rates compared to Ti due to virus-induced cytopathi-
city in vitro [15,32]. Free virions were produced by infected cells
and were cleared. With this description, we constructed
dynamical equations to predict the time-evolution of each of
the uninfected and infected cell subpopulations and the
population of free virions and compared our predictions with
experiments (Methods).
Model predictions
Triphasic viral kinetics in vitro. When cells with a log-
normal distribution of the CD81 expression level (Fig. 2A inset)
were exposed to virions in vitro, we found that infection proceeded
in three phases (Figs. 2A and B). In the first phase, the population
of uninfected cells, T, rose, as their net proliferation rate
dominated their loss rate by infection. At the same time,
exposure of T to virions resulted in the growth of infected cells,
I. Initially, because I was small, viral production was dominated
by clearance, resulting in a decline of the viral load, V.A sI
increased, viral production compensated for clearance and V
began to rise. Subsequently, V evolved proportionally to I,
indicating the establishment of a pseudo-steady state between viral
production and clearance, pI&cV.
In the second phase, V was sufficiently large that the loss of T
by infection outweighed cell proliferation, resulting in a decline of
T (Fig. 2A). This decline was consequently associated with a steep
rise in I and correspondingly V (Fig. 2B). In the third phase, T
rose again while I and V remained nearly constant. This third
Figure 1. Schematic of the model. (A) HCV enters a target cell if the
number of E2-CD81 complexes formed across the virus-cell pair, NC,
exceeds the threshold, NT
C (top), but not otherwise (bottom). (B) Viral
kinetics following the exposure of cells with a distribution of the CD81
expression level (left) to virions in vitro is determined by the time-
evolution of subpopulations 1 through K of cells with distinct CD81
expression levels and hence different susceptibilities to HCV entry
(right).
doi:10.1371/journal.pcbi.1002307.g001
Author Summary
The interaction between the hepatitis C virus (HCV)
envelope protein E2 and the host cell surface receptor
CD81 is critical for HCV entry into hepatocytes and
presents a promising drug and vaccine target. Yet, the
number of E2-CD81 complexes that must be formed
between a virus and a target cell to enable viral entry
remains unknown. Direct observation of the E2-CD81
complexes preceding viral entry has not been possible. We
constructed a mathematical model of HCV viral kinetics in
vitro and using it to analyze data from recent cell culture
studies obtained estimates of the threshold number of E2-
CD81 complexes necessary for HCV entry. We found that
depending on the E2-CD81 binding affinity, between 1 and
13 complexes are necessary for HCV entry into human
hepatoma-derived cells. Our study thus presents new,
quantitative insights into the molecular requirements of
HCV entry, which may serve as a guideline for intervention
strategies targeting the E2-CD81 interaction. Further, our
study shows that HCV viral kinetics in vitro can be
described using a mathematical model, thus facilitating
quantitative analyses of the wealth of data now emanating
from cell culture studies of HCV infection.
Number of E2-CD81 Complexes Required for HCV Entry
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cells, Ti, expressing different levels of CD81, which we describe
below.
Dependence of viral kinetics on CD81 expression. The
relative susceptibility of cells to infection, Si, depends on the CD81
expression level, ni, and the parameters NT
C and KD (equilibrium
dissociation constant or the inverse of affinity) (Eqs. (4) and (5)).
For fixed NT
C and KD, Si increased with ni (Fig. 2B inset). Above a
certain ni (&102 mm{2), CD81 did not limit entry and cells were
nearly completely susceptible to infection (Si&1). At the same
time, below a certain ni (&1mm{2), cells were refractory to
infection (Si&0). This variation in Si led to diverse kinetic profiles.
In the first phase of viral kinetics, all subpopulations Ti grew
because infection rates were low and cell proliferation dominated
(Fig. 2C). In the second phase, Ti declined for subpopulations with
sufficiently large Si that infection dominated proliferation (e.g.,
Si&0:5 and &1 in Fig. 2C). The corresponding Ii accordingly
rose (Fig. 2C lower inset). Eventually, nearly all cells in these
subpopulations were infected and Ti vanished leaving behind a
pool of infected cells. This pool remained constant over the &20 d
Figure 2. Model predictions of HCV viral kinetics in vitro. The time evolution of (A) uninfected cells, T, (B) infected cells, I, and viral load, V, (C)
uninfected cell sub-populations, Ti, and (lower inset) infected cell sub-populations, Ii, corresponding to Si&10{5 (dot-dashed line), 0.5 (dotted line)
and 1 (solid line), and (D) the total fraction of cells infected, y. The initial CD81 distribution, fn i ðÞ , as a function of the CD81 expression level, ni,i s
presented in the inset in (A). The three phases of infection are also marked in (A). Inset in (B) shows Si as a function of ni. Upper inset in (C) shows the
time evolution of the mean CD81 surface density. Inset in (D) shows the fractions of cells infected in sub-populations with distinct CD81 expression
levels, ji, at different post-infection times. In (A), (B), (D) and the upper inset in (C), NT
C~2 (red line), 4 (blue line), and 6 (green line). In (C) and the
inset in (D), NT
C~4. Other parameter values employed are l~0:44d
-1; m~1:7|10{4 d
-1; d~0:011d
-1; p~2:78ffu:(ml:d)
{1; c~23:2d
{1;
b~1:2|10{4 ml:(ffu:d)
{1;KD~1:7|10{4 M. Initial conditions are T(0)~3:7|104 cells; I(0)~0; V(0)~400ffu:ml
{1.
doi:10.1371/journal.pcbi.1002307.g002
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assumed was much larger, &100 d. Correspondingly, V also
remained nearly constant (Fig. 2B). In contrast, subpopulations
with low Si were not easily infected and continued to grow
throughout (e.g., Si&10{5 in Fig. 2C). The growth of the latter
cells resulted in the rise of T in the third phase of infection
(Fig. 2A).
Indeed, at any time tw0, the fraction of cells infected within any
subpopulation, ji, increased with ni (Fig. 2D inset). For large ni,
CD81 did not limit infection (Si&1) so that ji evolved
independently of ni. Eventually, all cells in the latter subpopula-
tions were infected and ji approached 1. Below a certain ni,
however, Si was so low that hardly any cells were infected and ji
remained vanishingly small. These latter subpopulations, refrac-
tory to infection, ultimately dominated the target cell population.
That a majority of the cells in the third phase was refractory to
infection was also evident from the time-evolution of the total
fraction of cells infected, y (Fig. 2D). y increased initially as cells
with high ni were infected. After a majority of the latter cells was
infected, I remained constant whereas the population of cells
refractory to infection increased, resulting in a decrease of y.
Accordingly, the mean CD81 expression also decreased (Fig. 2C
upper inset). Even with low susceptibility, however, stochastic
events may result in the formation of the threshold number of
complexes and allow viral entry. As Ti increased, the frequency of
such stochastic events grew and resulted in the growth of the
corresponding Ii (Fig. 2C lower inset), which in turn resulted in the
subtle rise of I and V towards the end of the third phase (Fig. 2B).
Influence of model parameters. As NT
C increased, Si
decreased (Fig. 2B inset), increasing the fraction of cells
refractory to infection and hence lowering y (Fig. 2D).
Accordingly, the rise of T in the third phase was enhanced
upon increasing NT
C (Fig. 2A). As T increased, the frequency of
stochastic events leading to entry into cells with low Si increased
and resulted in a slightly greater increase of I and V towards the
end of the third phase (Fig. 2B). Variations in other model
parameters introduced similar quantitative variations but did not
alter the triphasic kinetics qualitatively (Fig. S1). Below, we present
comparisons of our model with experiments.
Comparison with experiments
HCV viral kinetics in vitro. We considered first the
experiments of Zhong et al. [15], who measured the kinetics of the
growth of Huh-7.5.1 cells with and without exposure to JFH-1
virions. We solved model equations using the initial CD81
distribution corresponding to Huh-7.5 cells [13] (Methods) (Fig.
S2). We fit model predictions of the time-evolution of the population
of viable cells, Tv, and of the ratio of the populations of dead and
viable cells, Td=Tv, simultaneously to the corresponding
experimental data in the absence of infection (V~0). Our model
provided good fits to the data and yielded estimates of the
proliferation and death rates, l and m,o fu n i n f e c t e dH u h - 7 . 5 . 1
cells (Fig. 3A). It follows from our model that in the absence of
infection (V~0), Tv~T0 exp((l{m)t) and Td=Tv~m(1{1=Tv)=
(l{m)&m=(l{m),w h e r eT0 is the population of cells at the start of
infection. In agreement, Tv rose linearly on a semi-log plot and the
ratio Td=Tv remained nearly constant (Fig. 3A).
Using l and m estimated thus and recognizing that viral
production and clearance rapidly attain pseudo-steady state
(
dV
dt
&0, which implies that V&
pI
c
), we next fit our predictions
of the time-evolution of Tv, the ratio Td=Tv, and the viral load, V,
simultaneously to the corresponding measurements during infec-
tion (Vw0) using d, b, v (~p=c), and NT
C as adjustable
parameters for different values of KD. (We employed a truncated
Gaussian approximation to the Poisson probability for Si (Fig.
S3).) Model predictions again provided good fits to the data
(Fig. 3B and Fig. S4A) indicating the ability of our model to
capture experimental observations quantitatively.
The data were consistent with the triphasic viral kinetics
predicted by our model. Tv displayed an initial rise followed by a
plateau and a subsequent rise (Fig. 3B). V displayed an initial rise
and a plateau. The ratio Td=Tv rose initially, attained a maximum,
and then declined. In our model calculations, both T and I rose in
the first phase (Fig. 2), in agreement with the initial rise of Tv, which
is the sum of T and I, in the experiments. In the second phase, T
declined primarily due to infection, giving rise to I, which
maintained a nearly constant sum of T and I, consistent with the
plateau in Tv. In the third phase, I remained nearly constant or rose
marginally, whereas T rose significantly, in agreement with the
subsequent rise of Tv. Similarly, the rise of V in the second phase
followed by the plateau were also in agreement with the trends
predicted (Fig. 2). In the first phase, however, V initially declined
and then rose as I increased (Fig. 2). The data considered here were
collected from day 2 post-infection (Fig. 3B), by which period
pseudo-steady state between viral production and clearance is
expected to be established and the initial decline of V is therefore
not expected to be observed. Finally, the initial rise of Td=Tv
corresponded to the rise of I in the first and second phases; I had
lifespans shorter than T due to virus-induced cytopathicity so that
higher values of I resulted in greater Td. The subsequent drop in
Td=Tv corresponded to the rise of T in the third phase, which
increased Tv and also lowered the overall rate of cell death.
Threshold number of E2-CD81 complexes necessary for
entry. From the above fits, for each value of KD in the range
*10{5{10{4 M, we obtained a corresponding best-fit estimate
of NT
C (Fig. 4, Table S1). For example, NT
C~9 (95% CI: 6–13)
when KD~1:7|10{5 M and NT
C~3 (95% CI: 2–4) when
KD~1:7|10{4 M. The best-fits thus suggested that depending
on the affinity of E2 for CD81, between 1 and 13 E2-CD81
complexes across a virus-cell pair were necessary for the entry of
JFH-1 virions into Huh-7.5.1 cells.
Robustness of parameter estimates. To test the
robustness of our estimate of NT
C, we applied our model to the
analysis of two independent datasets of viral entry and kinetics in
vitro. Koutsoudakis et al. [13] exposed an equal mixture of Huh7-
Lunet and Lunet/CD81 cells to Jc1 virions at two different MOIs
and measured the fractions of cells infected in sub-populations
with distinct CD81 expression levels at day 3 post-infection. To
compare our model predictions with their data, we employed the
initial CD81 distribution obtained by averaging the distributions
on Huh7-Lunet and Lunet/CD81 cells (Fig. S2) and predicted the
fraction of cells infected in cell sub-populations with distinct CD81
expression levels, ji. We fixed l, m, and d to the values estimated
above (Table 1). The two initial MOIs employed would lead to
different pseudo-steady states between viral production and
clearance; i.e., V&
pI
c
would still hold, but the values of V and
I would be different when the pseudo steady state is reached in the
two cases. To account explicitly for the different initial MOIs
employed, we therefore relaxed the pseudo-steady state
approximation in our model. We obtained c, the viral clearance
rate, by fitting our model predictions without the pseudo-steady
state approximation to the above data of Zhong et al. [15] (Fig.
S5). We then fit our predictions of ji to the data of Koutsoudakis
et al. [13] with both the initial MOIs simultaneously using the
appropriate initial conditions and NT
C, p and b as adjustable
parameters for different values of KD. In effect, we assumed that
Number of E2-CD81 Complexes Required for HCV Entry
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Huh7.5 and the combination of Huh7-Lunet and Lunet/CD81,
affected the viral production rate and/or the infection rate.
Model predictions again provided excellent fits to the data
(Fig. 3C and Fig. S4B). For CD81 expression levels v0:1mm{2, ji
remained negligible for both MOIs, indicating that these
subpopulations were refractory to infection. For higher expression
levels, ji increased with CD81 expression and reached a plateau at
an expression level of *102 mm{2, beyond which viral entry was
not limited by CD81. The plateau attained different values for the
two MOIs, as expected from the different underlying viral kinetics.
With MOI of 5, ,90% of the cells with excess CD81 were infected
Figure 3. Comparisons with experiments. (A) Fits of model predictions (lines) to data [15] (symbols) of the time-evolution of the population of
viable cells, Tv, and the ratio of the populations of dead and viable cells, Td=Tv, in the absence of infection using l and m as adjustable parameters.
Initial conditions: T(2)~9|104 cells and Td(2)~40cells. (B) Fits of model predictions (lines) to data (symbols) [15] of the time-evolution of Tv, Td=Tv,
and the viral titre, V, using d, b, v(~p=c), and NT
C as adjustable parameters and with KD~1:7|10{4M. Initial conditions: V(2)~40ffu:ml
{1;
I(2)~vV(2); T(2)~9|104{I(2) cells; Td(2)~40 cells. (C) Fits of model predictions (lines) of fractions of cells infected in sub-populations with
distinct CD81 expression levels, ji, at day 3 post-infection to data [13] (symbols) using NT
C, p and b as adjustable parameters and with
KD~1:7|10{4 M. Initial conditions: T(0)~105 cells; I(0)~0; V(0)~105 TCID50 (MOI,1; circles) or 5|105 TCID50 (MOI,5; diamonds). Fits with
other values of KD are presented in Fig. S4. The best-fit parameters are in Tables S1 and S2. (D) Model prediction (line) of the time-evolution of the
fraction of cells infected, y, compared with data [14] (symbols). Initial conditions used: T(0)~3:7|104 cells; V(0)~12000ffu:ml
{1 (MOI*0:3);
I(0)~0. Other parameters are the same as in (A). Comparisons with other values of KD are presented in Fig. S4.
doi:10.1371/journal.pcbi.1002307.g003
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CD81 were infected. The resulting estimates of NT
C were in close
agreement with the estimates obtained above (Fig. 4 and Table
S2), giving us confidence in our model and our estimates of NT
C.
We note that model predictions of the total percentage of cells
infected, y, at MOI 5 and 1 (,31% and ,23%, respectively) were
lower than the corresponding measurements (57% and 29%). We
found that altering the initial mixture (1:4 Huh7-Lunet and
Lunet/CD81 cells) or the initial distribution of CD81 expression
brought our predictions (,50% and ,30%, respectively) close to
the experiments. Fits to the data and the resulting estimates of NT
C
remained unaltered; the only differences were in the estimates of p
and b, again indicating the robustness of the estimates of NT
C.
We considered finally the experiments of Tscherne et al. [14],
where the fraction of Huh 7.5 cells infected with J6/JFH virus was
measured as a function of time following the onset of infection. We
solved our model equations without any adjustable parameters
and with the appropriate initial conditions and predicted the time-
evolution of the fraction of cells infected, y (Fig. 3D). Following
the onset of infection, y increased and reached a maximum of
90% at day 5 post-infection. Subsequently, cells refractory to
infection began to outgrow the susceptible population and y
decreased, reaching ,20% by day 17 post-infection. Our model
captured the measured evolution of y quantitatively (Fig. 3D and
Fig. S4C). The agreement between model predictions without any
adjustable parameters and experimental observations represented
a successful validation of our model as well as the parameter
estimates obtained above.
Discussion
Analysis of experimental data using mathematical models has
provided crucial insights into disease pathogenesis and the
effectiveness of drugs and established guidelines for rational
optimization of therapy for HCV infection [21–31,33,34]. The
recent development of cell culture systems that allow persistent
HCV infection in vitro [35–38] has yielded a wealth of new data
on HCV replication, evolution, and the impact of drugs. Analysis
of this data is expected to provide further insights into HCV
pathogenesis and outcomes of therapy, but has been precluded by
the lack of mathematical models of HCV viral kinetics in vitro.
Indeed, significant efforts are underway to construct models of the
intracellular replication and evolution of HCV with the aim of
elucidating the activity of direct acting antiviral drugs [39–41].
Here, we have constructed a mathematical model of HCV viral
kinetics in vitro. Applying it to the analysis of data from several
recent cell culture studies, we obtained quantitative insights into
the molecular requirements of HCV entry. We estimated that
depending on the binding affinity of E2 and CD81, between 1 and
13 E2-CD81 complexes are necessary for HCVcc entry into
human hepatoma-derived cells.
Our estimate provides a quantitative guideline for the optimal
usage of drugs and vaccines that target the E2-CD81 interaction:
A potent drug or vaccine must ensure that not more than 1–13 E2-
CD81 complexes are formed across a virus-cell pair in order to
prevent viral entry. This guideline assumes significance as drugs
that target the E2-CD81 interaction are under development
[11,12] and may become part of future treatments involving direct
acting antiviral agents that seek to overcome the limitations of the
current interferon-ribavirin-based treatments [42]. Further, a
recent analysis of the HCV quasispecies in six patients who
Figure 4. Threshold number of E2-CD81 complexes. Estimates of
NT
C for different values of KD obtained from fits of model predictions to
the data of Zhong et al. [15] (circles) and Koutsoudakis et al. [13]
(diamonds) (Fig. S4). Error bars are 95% confidence intervals.
doi:10.1371/journal.pcbi.1002307.g004
Table 1. Summary of model parameters and their values employed.
Parameter Description Value (95% CI)
a Source
l Proliferation rate of target cells 0.44 (0.43–0.46) d
21 Best-fit (Fig. 3A)
m Death rate of target cells 1.7 (1.4–2.0)610
24 d
21 Best-fit (Fig. 3A)
d Death rate of infected cells 1.1 (0.4–1.8)610
22 d
21 Best-fit (Fig. 3B)
b Infection rate of cells with excess CD81 expression 1.2 (0.6–1.8)610
24 mlN(ffuNd)
21 Best-fit (Fig. 3B)
v Ratio of viral production rate per cell (p) and clearance rate (c) 0.12 (0.06–0.19) ffuNml
21 Best-fit (Fig. 3B)
c Clearance rate 23.2 d
21 Best-fit (Fig. S5)
KD Equilibrium dissociation constant of the E2-CD81 binding reaction 10
24–10
25 M Varied
nE Number density of E2 molecules on HCV 2.3610
4 mm
22 [53]
A Virus-cell contact area 1.3610
23 mm
2 [54]
aTypical values employed. Variations are indicated in the text and in figure legends.
doi:10.1371/journal.pcbi.1002307.t001
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of more efficient entry, achieved through modulation of the CD81
dependence of viral entry, were selected following liver transplan-
tation [8]. Blocking E2-CD81 interactions effectively, for which
our estimate presents a quantitative criterion, may thus be a
promising avenue to prevent graft reinfection following liver
transplantation.
In an earlier study, Koutsoudakis et al. [13] estimated that a cell
must express .70000 CD81 molecules to allow HCV entry. This
threshold was identified as follows. In independent experiments,
cells with widely varying distributions of CD81 were exposed to
HCV at low MOI in culture and the percentage of cells infected at
day 5 was measured. This latter percentage was found to correlate
well with the percentage of cells initially expressing .70000 CD81
molecules/cell. For instance, with Huh7.5 cells, the percentage of
cells infected at day 5 was 91.5 and the percentage expressing
.70000 CD81 molecules/cell at day 0 was 93, and with Huh7-
Lunet cells, which express fewer CD81 molecules than Huh7.5
cells, the percentages were 11.2 and 17, respectively. Based on this
correlation, Koutsoudakis et al. suggested 70000 CD81 mole-
cules/cell as the threshold for entry. Our present analysis suggests
that the underlying viral kinetics may render this estimate an
upper bound. Virus-induced cytopathicity in culture would result
in the loss of susceptible cells and therefore a continuous decrease
in the frequency of susceptible cells with time. Consequently, the
percentage of cells susceptible initially is expected to be higher
than the percentage of cells susceptible–and hence even higher
than the percentage infected–at day 5 post-infection. The higher
percentage of cells susceptible initially would therefore imply a
threshold smaller than 70000 molecules/cell. This is also evident
in the experiments of Koutsoudakis et al., where cells with lower
CD81 expression (MFI,50) than 70000 molecules/cell
(MFI,100) were infected (see Fig. 3C). From our analysis, we
identified the threshold number of E2-CD81 complexes and not
CD81 molecules necessary for entry. Because stochastic events can
result in the formation of the requisite number of complexes, cells
expressing few CD81 molecules have small but nonzero
susceptibilities to infection. Indeed, we found using parameters
employed in Fig. 3D that a small percentage of cells expressing as
few as ,10000 CD81 molecules was infected by day 5. More
recently, Zhang et al. [18] have argued that a substantially smaller
expression level than suggested by Koutsoudakis et al. may suffice
for entry and that CD81 may also be necessary, perhaps at higher
expression levels, for post-entry events. Our model does not
distinguish between entry and post-entry requirements of CD81.
Our estimate of 1–13 E2-CD81 complexes defines successful
infection of a cell and combines the requirements for entry and
any post-entry steps [17,18].
Our model yielded good fits to data with KD in the range
*10{5{10{4 M, which is higher than the value, *10{7 M,
determined using recombinant E2 and soluble CD81 [43]. (Fits
with KD*10{7 M were poor (not shown).) This discrepancy may
be because the binding affinity when the proteins are in solution
may be different from that when the proteins are restricted to
membranes [44], recombinant E2 may not accurately mimic the
true E2-CD81 interaction [45], and/or only a fraction of the
CD81 may lie outside tetraspanin-enriched microdomains and/or
be associated with CLDN1 and therefore available for binding E2
[10,46]. The E2-CD81 binding affinity in situ remains to be
determined. Our model yielded best-fit values of the threshold
number of complexes, NT
C, that decreased as KD increased (Fig. 4).
For a given CD81 expression level, the mean number of E2-CD81
complexes formed decreased as KD increased, lowering suscepti-
bility (Eqs. (4) and (5)). Decreasing NT
C restored this susceptibility
(Fig. 2B inset and Fig. S6), thus ensuring that the resulting viral
kinetics was conserved and in agreement with data. This does not
imply, however, that viral strains with lower E2-CD81 affinity
(higher KD) would require fewer E2-CD81 complexes for entry.
On the contrary, given a value of NT
C, our model predicts that a
cell would be less susceptible to entry of viral strains with higher
KD.
Our model was designed to mimic experiments that examined
the influence of CD81 expression on viral entry and kinetics [13–
15]. In these experiments, cells with high CD81 expression were
preferentially infected and lost due to virus-induced cytopathicity,
and cells with low CD81 expression, refractory to infection,
eventually dominated the culture, suggesting that CD81 expres-
sion limited entry. Accordingly, our model assumed that other
entry receptors were not limiting. Our model then predicted
triphasic viral kinetics in vitro, in agreement with experiments. We
note that the origins of the triphasic pattern here are distinct from
the triphasic viral load decline in some patients undergoing
combination therapy, the latter due to liver homeostatic
mechanisms [25]. Further, the triphasic kinetics is a short-term
phenomenon (,2–3 weeks). Over longer periods, viral evolution
may alter the kinetics substantially [15], which our model does not
consider. Nonetheless, our model can be readily adapted to the
scenario where a receptor other than CD81 is limiting and may
thus serve to quantify the requirements of that receptor for HCV
entry.
We recognize a few additional simplifications in our model. First,
our model ignored cell-cell transmission of infection. CD81 appears
to be necessary for direct cell-cell transmission [47]. If the
susceptibility of a cell to cell-cell transmission depends on CD81
expressionin amanner similar toits susceptibility toviral entry, which
remains to be ascertained, then we can show that our model with the
pseudo-steady state approximation, pI&cV, implicitly accounts for
cell-cell transmission: the net infection rate from both modes,
bVSiTiVzbISiTiI&bVSiTiVzbISiTi(cV=p)~bSiTiV,i si n
agreement with our model (Eq. (1)) with b an effective infection
rate constant that lumps the rate constants of infection by free
virions, bV, and cell-cell transmission, bI. Second, our model
assumes that reaction equilibrium is attained rapidly compared to
viral entry and that the diffusion of CD81 on the target cells
continually replenishes the free CD81 in the virus-cell contact
region lost due to binding. Accordingly, our model predicts an
upper bound on the mean number of E2-CD81 complexes
formed in the contact region. Thus, if CD81 diffusion or its
binding with E2 were rate limiting, a threshold smaller than 1–13
E2-CD81 complexes is expected to describe the data we
considered. Finally, we ignored the splitting of cell culture at
confluence. We employed the data at day 3 post-infection from
Koutsoudakis et al. [13], when cells are not expected to have
reached confluence. Further, the best-fit parameter estimates
obtained from the data of Koutsoudakis et al. [13] were close to
those from Zhong et al. [15] (Fig. 4). Also, accounting for splitting
did not significantly alter our comparisons with the data of
Tscherne et al. [14] so long as the splitting was performed after
day 5 post-infection (Fig. S7). Also, including a logistic term to
limit the proliferation of cells as they approached confluence did
not alter our parameter estimates significantly (not shown).
Nonetheless, that model predictions described several indepen-
dent experimental observations quantitatively indicated that even
with the above simplifications our model captured the essential
features of HCV viral kinetics in vitro successfully. At the same
time, the simplifications restricted model parameters to a number
that allowed robust parameter estimation through fits to available
data.
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Model of HCV kinetics in vitro
We considered in vitro experiments where a population of
uninfected cells, T, is exposed to a population of HCVcc virions,
V. We divided the cells into K subpopulations, denoted Ti, where
i~1,2,::,K, with cells in each subpopulation expressing CD81 in a
range Dni around ni molecules per unit area. At the start of
infection (t~0), the variation of Ti with ni was determined from a
known distribution, f(ni), of CD81 expression levels across cells
(Fig. 1). The following equations described the ensuing viral
kinetics (tw0):
dTi
dt
~ l{m ðÞ Ti{bSiTiV, i~1,2,::,K ð1Þ
dIi
dt
~bSiTiV{dIi, i~1,2,::,K ð2Þ
dV
dt
~p
X K
i~1
Ii{cV ð3Þ
Here, l and m are the proliferation and death rates of Ti. b is the
infection rate of cells expressing excess CD81. d is the death rate of
Ii. Following observations of HCV-induced cell cycle arrest in
vitro [32,48], we neglected the proliferation of Ii. p and c are the
per cell production rate and the clearance rate of free virions,
respectively. Here, c represents the combined rate of the natural
degradation of virions, the loss of viral infectivity, and the loss of
virions due to entry and attachment [49,50]. For simplicity, we
assumed c to be a constant.
To determine Si, we considered a cell Ti, with CD81 expression
level ni, closely apposed to a virion with nE E2 molecules per unit
area. We assumed, as with HIV [20], that the E2-CD81
interactions across the virus-cell interface attain equilibrium well
before viral entry. If B is the surface density of E2-CD81
complexes, C that of unbound CD81 and E that of unbound E2
molecules in the contact area, then at equilibrium B~
EC
KM
D
, where
KM
D is the equilibrium dissociation constant of E2-CD81
complexes when the proteins are restricted to membranes. From
Bell’s analysis, KM
D ~(4=3)RKD, where KD is the equilibrium
dissociation constant when the proteins are in solution and
R~0:75nm is the encounter distance between the proteins for
bond formation [51]. The virus-cell contact area, A, is small
compared to the surface area of the cell. Further, free CD81 can
diffuse on the cell membrane and therefore be recruited to the
contact area. Consequently, C is expected not to decrease
substantially below ni, as suggested also by an independent
reaction-diffusion model [52]. In contrast, the viral surface area is
comparable to A and assuming E2 to be less mobile than CD81, it
follows that the surface density of E2 in the contact area obeys the
species balance equation: EzB~nE. Under the latter two
constraints, the mean number of complexes formed across the
virus-cell contact at equilibrium, NC, is given by
NC~
nEniA
KM
D zni
ð4Þ
We recognized next that the E2 expression level on the virion
and the virus-cell contact area are subject to stochastic variations.
We assumed therefore that the number of complexes formed
during a virus-cell contact, NC, follows a Poisson distribution with
mean NC. Viral entry (and subsequently infection) occurred if
NC§NT
C, where NT
C is the threshold number of E2-CD81
complexes necessary for HCV entry. The probability that
NC§NT
C,
Si~e{NC
X ?
X~NT
C
XNC
X!
, ð5Þ
thus yielded the relative susceptibility to infection of a cell with
CD81 expression level ni. (The Poisson distribution does allow NC
to exceed the limit of 180 set by the number of E2 molecules
present on a virion, but in all our calculations NC remained fewer
than 30 (Fig. S8) so that the probability that NC§180 was
negligibly small.)
Equations (1)–(5) yielded a model of HCV kinetics in vitro that
accounted explicitly for the dependence of viral entry on the CD81
expression level on cells.
Model parameters and calculations
We solved model equations using a computer program written
in MATLAB and computed quantities measured experimentally,
namely, the time-evolution of the populations of uninfected and
infected cells, T~
P K
i~1
Ti and I~
P K
i~1
Ii, the viral titre, V, the
fraction of cells infected, y~
I
IzT
, the fraction of cells infected
within each subpopulation, ji~
Ii
IizTi
, i~1,2,::,K, and the
populations of viable and dead cells, Tv~TzI and
Td~
Ð t
0
(mT(s)zdI(s))ds, respectively.
We employed the following parameter values and initial
conditions: nE~2:3|104mm{2 corresponding to 180 E2 mole-
cules on a virion with average diameter 50 nm [53];
A~1:3|10{3mm2, corresponding to a virus-cell contact radius
of 20nm [54]; the target cell diameter was 60mm [17]; KD was
varied over the range *10{5{10{4 M (see above). The initial
CD81 expression was assumed to follow the log-normal distribu-
tion, fn i ðÞ ~
1
nis
ﬃﬃﬃﬃﬃﬃ
2p
p e
{
(lnni{n)2
2s2 , where n and s were the mean and
standard deviation of ln ni. For comparisons with experimental
data, the initial distributions were obtained from measurements
(Fig. S2; see below). Thus, the initial cell subpopulations,
Ti(0)~f(ni)DniT(0), where T(0) was the total initial target cell
population. We divided the range of CD81 expression levels into
K~80 intervals, which determined Dni; finer discretisation did
not improve the accuracy of our solution (Fig. S1). The remaining
parameters, estimated from fits to data, are listed in Tables S1 and
S2. We have summarized model parameters in Table 1.
Data and fitting
We considered data from three recently published cell culture
studies of HCV kinetics. First, we considered data of Zhong et al.
[15], where Huh-7.5.1 cells were exposed to JFH-1 virions and the
kinetics of infection followed for 21 d. Specifically, we employed
the data of the time-evolution of the supernatant infectivity, the
population of attached (viable) cells, and the ratio of the
populations of floating (dead) and attached cells, the latter two
datasets with mock infection as well as with HCVcc infection (Fig.
S1 in [15]). Second, we considered data of Koutsoudakis et al.
[13], where a 1:1 mixture of Huh7-Lunet and Lunet/CD81 cells
was exposed to HCVcc Venus-Jc1 virus and the fractions of cells
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were measured after 72 h. The initial viral population was at an
MOI of ,5 and ,1 TCID50/cell (where TCID50 is the 50% tissue
culture infective dose), respectively, in two independent experi-
ments (Fig. 5 in [13]). Third, we considered the data of Tscherne
et al. [14], where Huh7.5 cells were exposed to J6/JFH virus and
the time-evolution of the fraction of cells infected as well as of the
distribution of CD81 expression levels across cells was followed for
17 d (Fig. 8 in [14]).
The CD81 expression on cells is usually measured in terms of
fluorescent intensity. To convert the measurements to CD81
surface densities, we adopted the following procedure. Measured
distributions of the CD81 expression level on Huh-7.5 (silRR) cells
were digitized from Zhang et al. [55] and on Huh-7.5 cells from
Koutsoudakis et al. [13]. The log-normal distribution,
y~
A
x
e
{
(lnx{n)2
2s2 , yielded good fits to the data (Fig. S9). The best-
fit parameter values (95% CI) were nZ =4.29 (4.27–4.31) and
sZ =0.45 (0.43–0.47) for the data of Zhang et al. and nK =6.1
(6.07–6.12) and sK =0.7 (0.67–0.72) for the data of Koutsoudakis
et al. Because the same cell lines were used, the underlying
distributions of CD81 expression are expected to be similar in the
two experiments. The differences in the reported fluorescence
intensities may therefore be attributed to different conversions of
CD81 surface density to fluorescence intensity in the two
measurements. To unravel the underlying distribution, we
assumed that log fluorescence intensity was linearly proportional
to log CD81 surface density (or that the fluorescence intensity had
a power law dependence on the surface density). Thus, a cell with
CD81 surface density ni would yield a fluorescence intensity zi and
ki in the measurements of Zhang et al. and Koutsoudakis et al.,
respectively, such that lnni~azblnzi and lnni~czd lnki,
where a, b, c, and d are constants. To determine the latter
constants, we employed the following observations: The mean
surface density of CD81 for the Huh-7 cell line is 2610
5
molecules/cell [3], which corresponded to a fluorescence intensity
of 48 units in the measurements of Zhang et al., so that
ln2|105~azbln48. Also, Koutsoudakis et al. measured the
number of CD81 molecules/cell corresponding to a fluorescence
intensity of 100 units and found it to be 7610
4 molecules/cell, so
that ln7|104~czd ln100. Further the above relationship
between fluorescence intensity and CD81 expression also implied
that azblnvz~czd lnvk and bsZ~dsK. Solving the latter
equations using the best-fit parameters above, we obtained a=2.8,
b=2.43, c=3.96 and d=1.56, which enabled conversion of
measured fluorescence intensities to CD81 surface densities, ni
(Fig. S2). The measured distributions in terms of counts versus
fluorescence intensities were then converted to probability
distributions, fn i ðÞ versus ni, by normalizing the counts such that
the areas under the fn i ðÞ versus ni curves equalled unity. The
resulting distributions (Fig. S2) were employed as the initial CD81
distributions for our fits to data (Fig. 3).
We digitized data using Engauge digitizer and fit model
predictions to data using the nonlinear regression tool NLINFIT
in MATLAB.
Supporting Information
Figure S1 Sensitivity to model parameters. Time-evolu-
tion of (A) uninfected cells, T, (B) infected cells, I, (C) viral load, V,
and (D) the fraction of cells infected, y, obtained by varying (I) the
equilibrium dissociation constant, KD =1.7610
25 M (thick solid
line), 3.3610
25 M (thin solid line), and 1.7610
24 M (dashed line),
(II) the mean of the log initial CD81 expression level, n=29.8
(thick solid line), 31.8 (thin solid line), and 33.8 (dashed line), (III)
the initial viral load, V0 =40 ffu?ml
21 (thick solid line),
400 ffu?ml
21 (thin solid line), and 4000 ffu?ml
21 (dashed line),
(IV) the infection rate constant, b=1.2610
23 ml?(ffu?d)
21 (thick
solid line), 1.2610
24 ml?(ffu?d)
21 (thin solid line), and
1.2610
25 ml?(ffu?d)
21 (dashed line), (V) the viral production rate,
p=0.278 ffu?(ml?d)
21 (thick solid line), 2.78 ffu?(ml?d)
21 (thin
solid line), and 27.8 ffu?(ml?d)
21 (dashed line), and (VI) the
number of cell sub-populations, K =40 (thick solid line), 80 (thin
solid line), and 120 (dashed line). (The three curves in (VI) are
indistinguishable.)
(TIF)
Figure S2 Initial distribution of the CD81 expression
level on target cells. Distribution of the CD81 expression level
on (A) Huh-7.5 cells and (B) Huh7-Lunet cells (diamonds) and
Lunet/CD81 cells (circles) obtained by digitizing data from
Koutsoudakis et al. (2007) J Virol 81:588–598 and converting
fluorescence intensities to CD81 surface densities (Methods).
(TIF)
Figure S3 Approximating the Poisson distribution with
a truncated Gaussian distribution. Model predictions of the
susceptibility of cells using the Poisson distribution,
Si~e{NC P ?
X~NT
C
XNC
X!
(dashed line), and an equivalent truncated
Gaussian distribution with mean NC and standard deviation
ﬃﬃﬃﬃﬃﬃﬃ
NC
p
, which yields Si~
erfc
NT
C{0:5 ðÞ {NC ﬃﬃﬃﬃﬃﬃﬃ
2NC
p
  
erfc {
ﬃﬃﬃﬃﬃ
NC
2
q    (solid line), where
erfc z ðÞ ~
2
ﬃﬃﬃ
p
p
ð ?
z
exp({t2)dt is the complementary error function,
for different values of NT
C and for (A) KD =1.7610
25 M and (B)
KD =3.3610
24 M.
(TIF)
Figure S4 Comparisons of model predictions with data
using different values of KD. (A) The fit in Fig. 3B repeated
with KD =1.7610
25 M (thick solid line), 3.3610
25 M (thin solid
line), 1.7610
24 M (dashed line), and 3.3610
24 M (dotted line).
The resulting best-fit parameter estimates are in Table S1. (The
fits for different KD nearly overlap and are indistinguishable.) (B)
Fits in Fig. 3C repeated with the above values of KD. The resulting
best-fit parameter estimates are in Table S2. (C) The comparison
in Fig. 3D repeated with the above values of KD and other
parameter values in Table S1.
(TIF)
Figure S5 Fits without the pseudo-steady state approx-
imation. The pseudo-steady state approximation is relaxed and
our model predictions (Eqs. (1)–(5)) are fit to the data inFig. 3B using
theparameterestimatesinTableS1andwithviralclearanceratecas
an adjustable parameter. Initial conditions used are: T(0)=3.7 610
4
cells; V(0)=400 ffu?ml
21; Td(0)=I(0)=0. The resulting estimates
of c are 21.4, 22.7, 23.2 and 23.8 d
21 for KD~1.7610
25,
3.3610
25,1 . 7 610
24, and 3.3610
24 M, respectively. (The fits for
different KD nearly overlap and are indistinguishable.)
(TIF)
Figure S6 Susceptibility of cells predicted using differ-
ent best-fit parameter combinations. Dependence of Si on
CD81 expression predicted using the parameter combinations in
(A) Table S1 and (B) Table S2 where KD =1.7610
25 M (thick
solid line), 3.3610
25 M (thin solid line), 1.7610
24 M (dashed
line), and 3.3610
24 M (dotted line).
(TIF)
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confluence. Model predictions of the fraction of cells infected
without splitting (thick line), splitting at day 6 and day 12 (thin
line), and splitting at day 8 and day 12 (dashed line) after the onset
of infection compared with the data in Fig. 3D (symbols).
Parameters used are the same as in Fig. 3D.
(TIF)
Figure S8 Mean number and probability of formation
of E2-CD81 complexes. (A) Model predictions of the mean
number of E2-CD81 complexes formed, NC, as a function of
CD81 expression for KD =1.7610
25 M (solid line), 3.3610
25 M
(dashed line), 1.7610
24 M (dashed-dotted line), and 3.3610
24 M
(dotted line). (B) Model predictions of the Poisson probability of
forming NC E2-CD81 complexes (Eq. (5)) when NC~1 (solid line)
and NC~30 (dashed line).
(TIF)
Figure S9 Conversion of fluorescence intensity to CD81
expression. Measured distributions of the CD81 expression level
on Huh-7.5 (silRR) cells digitized from Zhang et al. (2004) J Virol
78:1448–1445 (diamonds) and Huh-7.5 cells from Koutsoudakis et
al. (2007) J Virol 81:588–598 (triangles). Lines are best-fits of the
log-normal distribution, y~
A
x
e
{
(lnx{n)
2
2s2 , to the data. The best-fit
parameter values (95% CI) are nZ =4.29 (4.27–4.31) and
sZ =0.45 (0.43–0.47) for the data of Zhang et al. and nK =6.1
(6.07–6.12) and sK =0.7 (0.67–0.72) for the data of Koutsoudakis
et al.
(TIF)
Table S1 Estimates of model parameters obtained from
fits of model predictions to the data in Figs. 3B and S4A.
95% confidence intervals are indicated in brackets.
(DOC)
Table S2 Estimates of model parameters obtained from
fits of model predictions to the data in Figs. 3C and S4B.
95% confidence intervals are indicated in brackets.
(DOC)
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